Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.
Inclusion criteria:
• 18 years of age or older
• Histologic evidence of malignancy (including melanoma, lung cancer, or other malignancies for which treatment with an anti-PD-1 or anti PD-L1 monoclonal antibody is deemed appropriate)
• Recommendation by the treating provider to initiate therapy with a commercially available, FDA approved, anti-PD-1 or anti PD-L1 monoclonal antibody
• An understanding of the protocol and its requirements, risks, and discomforts
• The ability and willingness to sign an informed consent
Exclusion criteria:
• Pregnancy or lactation (for females)
• Inability on the part of the patient to understand the informed consent or be compliant with the protocol
• Any condition, which in the opinion of the patient’s treating oncologist, or the provider performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient (including a history of a serious or life-threatening allergic reaction to such local anesthetics as lidocaine or xylocaine)
Provisions for the inclusion of minorities: All eligible patients will be encouraged to enroll regardless of ethnicity, gender, or race.